Humacyte to Host Virtual KOL Event to Discuss Case Studies on the Use of Acellular Tissue Engineered Vessel (ATEV™) in Vascular Trauma Treatment on September 30, 2024 DURHAM, N.C., Sept. 26, 2024 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable, bioengineered human tissue at commercial scale, today announced it will host a virtual KOL event on Monday, September 30, 2024 at 8:00 AM ET. To register, . The event will feature Charles Fox, MD (University of Maryland School of Medicine), Rishi Kundi MD, RPVI, ...
VANCOUVER, British Columbia--(BUSINESS WIRE)-- (Nasdaq: ABCL) will announce its third quarter 2024 financial results on Monday, November 4, 2024, and hold an earnings conference call at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) the same day. A live audio webcast of the earnings conference may be accessed through a link that will be posted on . A replay will be available through the same link following the conference call. About AbCellera Biologics Inc. (Nasdaq: ABCL) discovers and develops antibody medicines for indications across therapeutic areas including cancer, metabolic and en...
Humacyte Announces Allowance of U.S. Patent Covering BioVascular Pancreas (BVP™) - New U.S. patent covers the design and composition of the BVP - - Positive results from ongoing preclinical studies support the potential of the BVP to deliver insulin-producing islets as a potential treatment for type 1 diabetes - DURHAM, N.C., Sept. 19, 2024 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable, bioengineered human tissue at commercial scale, today announced the allowance of a U.S. Patent covering its...
Treace Highlights New Product Innovations and Updated Clinical Study Data at the American Orthopaedic Foot & Ankle Society Annual Meeting 2024 PONTE VEDRA, Fla., Sept. 11, 2024 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities through its flagship and Procedures, today announced it will highlight new product innovations and present new interim data for the ALIGN3D™ and Mini3D™ Lapiplasty® clinical studies at the Ameri...
Humacyte to Participate at Upcoming Investor Conferences in September DURHAM, N.C., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable, bioengineered human tissue at commercial scale, today announced that Laura Niklason, M.D., Ph.D., Founder, President, and Chief Executive Officer, and Dale Sander, Chief Financial Officer, will represent Humacyte at the following conferences in September. H.C. Wainwright 26th Annual Global Investment Conference Format: Company Presentation Date: Tuesday, Sep...
NCL Corporation Ltd. Announces Proposed Offering of Senior Notes MIAMI, Sept. 03, 2024 (GLOBE NEWSWIRE) -- NCL Corporation Ltd. (“NCLC”), a subsidiary of Norwegian Cruise Line Holdings Ltd. (NYSE: NCLH), announced today that it is proposing to sell $315.0 million aggregate principal amount of its senior notes due 2030 (the “Notes”) in a private offering (the “Notes Offering”) that is exempt from the registration requirements of the Securities Act of 1933, as amended (the “Securities Act”). We intend to use the net proceeds from the Notes Offering, together with cash on hand, to redeem $3...
Two Directors at Norwegian Cruise Line Holdings Ltd sold 55,000 shares at between 18.092USD and 18.094USD. The significance rating of the trade was 61/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's ...
VANCOUVER, British Columbia--(BUSINESS WIRE)-- (Nasdaq: ABCL) today announced that executives from the Company will be presenting at the following investor conferences: Wells Fargo Healthcare Conference on Thursday, September 5, 2024, at 12:00 p.m. Pacific Time (3:00 p.m. Eastern Time) Cantor Global Healthcare Conference on Tuesday, September 17, 2024, at 8:30 a.m. Pacific Time (11:30 a.m. Eastern Time) Live audio webcasts of each presentation may be accessed through links that will be posted on . Replays of each webcast will be available through the same links following the presenta...
Humacyte Presents Positive Long-Term Results of ATEV™ in Treatment of Vascular Trauma in Military Setting from Ukraine Humanitarian Program - Results presented at the Department of Defense’s Military Health System Research Symposium (MHSRS) - - In real-world military setting the ATEV was observed to have 12-month patency of 87.1% - - There were zero instances of infection, amputation or death during the long-term follow-up period despite the severity of the wartime injuries treated - DURHAM, N.C., Aug. 27, 2024 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotech...
Treace Announces Participation in the Morgan Stanley 22nd Annual Global Healthcare Conference PONTE VEDRA, Fla., Aug. 22, 2024 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities through its flagship and Procedures, today announced that John T. Treace, Chief Executive Officer, and Mark L. Hair, Chief Financial Officer, will participate in a fireside chat at the Morgan Stanley 22nd Annual Global Healthcare Conference on ...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.